@article{d354b3281c7348eeb0cfb0e0fb64dbd5,
title = "X-change symposium: status and future of modern radiation oncology—from technology to biology",
abstract = "Future radiation oncology encompasses a broad spectrum of topics ranging from modern clinical trial design to treatment and imaging technology and biology. In more detail, the application of hybrid MRI devices in modern image-guided radiotherapy; the emerging field of radiomics; the role of molecular imaging using positron emission tomography and its integration into clinical routine; radiation biology with its future perspectives, the role of molecular signatures in prognostic modelling; as well as special treatment modalities such as brachytherapy or proton beam therapy are areas of rapid development. More clinically, radiation oncology will certainly find an important role in the management of oligometastasis. The treatment spectrum will also be widened by the rational integration of modern systemic targeted or immune therapies into multimodal treatment strategies. All these developments will require a concise rethinking of clinical trial design. This article reviews the current status and the potential developments in the field of radiation oncology as discussed by a panel of European and international experts sharing their vision during the “X-Change” symposium, held in July 2019 in Munich (Germany).",
author = "Stefanie Corradini and Maximilian Niyazi and Dirk Verellen and Vincenzo Valentini and Se{\'a}n Walsh and Anca-L. Grosu and Kirsten Lauber and Amato Giaccia and Kristian Unger and Debus, {J. rgen} and Pieters, {Bradley R.} and Matthias Guckenberger and Suresh Senan and Wilfried Budach and Roland Rad and Julia Mayerle and Claus Belka",
note = "Funding Information: CB, SC and MN received research grants from Elekta, Viewray and Brainlab. DV has an on going collaboration with SunNuclear Inc, Sordina IORT Technologies and RaySearch. SW holds a leadership position and shares in the MedTech company OncoRadiomics SA. BRP received a research grant from Elekta. SS has received departmental research grants from Varian Medical Systems, ViewRay Inc. and AstraZeneca, and personal fees from AstraZeneca, Celgene and MSD. MG received advisory board and honoraria from AstraZeneca and research support from AstraZeneca, ViewRay and Varian. JD reports grants from Viewray Inc, CRI The Clinical Research Institute GmbH, Accuray International Sari, RaySearch Laboratories AB, Vision RT Limited, Merck Serono GmbH, Astellas Pharma GmbH, Astra Zeneca GmbH, Siemens Healthcare GmbH, Solution Akademie GmbH, Egomed PLC Surrey Research Park, Quintiles GmbH, Pharmaceutical Research Associates GmbH, Boehringer Ingelheim Pharma GmbH&CoKG, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix S.A outside the submitted work. VV has received departmental research grants from Varian Medical Systems, ViewRay Inc., Elekta, Merck-Serono, Roche. The other authors declare that they have no competing interests. Publisher Copyright: {\textcopyright} 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = dec,
day = "1",
doi = "https://doi.org/10.1186/s13014-021-01758-w",
language = "English",
volume = "16",
pages = "1",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",
}